# Study of the Safety and Immunogenicity of NasoVAX Extension

> **NCT03760549** · — · COMPLETED · sponsor: **Altimmune, Inc.** · enrollment: 8 (actual)

## Conditions studied

- Influenza

## Interventions

- **DRUG:** Subjects were administered NasoVAX high dose

## Key facts

- **NCT ID:** NCT03760549
- **Lead sponsor:** Altimmune, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-21
- **Primary completion:** 2019-02-18
- **Final completion:** 2019-02-18
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2025-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03760549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03760549, "Study of the Safety and Immunogenicity of NasoVAX Extension". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03760549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*